DK2814514T3 - Histidyl-tRNA-synthetaser til behandling af autoimmune og inflammatoriske sygdomme - Google Patents

Histidyl-tRNA-synthetaser til behandling af autoimmune og inflammatoriske sygdomme Download PDF

Info

Publication number
DK2814514T3
DK2814514T3 DK13749967.9T DK13749967T DK2814514T3 DK 2814514 T3 DK2814514 T3 DK 2814514T3 DK 13749967 T DK13749967 T DK 13749967T DK 2814514 T3 DK2814514 T3 DK 2814514T3
Authority
DK
Denmark
Prior art keywords
hrs
present disclosure
hrs polypeptide
polypeptide
disease
Prior art date
Application number
DK13749967.9T
Other languages
English (en)
Inventor
Ching Fun Lau
Wing-Sze Lo
Kyle P Chiang
Elisabeth Gardiner
Jeffrey Greve
Melissa Ashlock
John D Mendlein
Original Assignee
Atyr Pharma Inc
Pangu Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atyr Pharma Inc, Pangu Biopharma Ltd filed Critical Atyr Pharma Inc
Application granted granted Critical
Publication of DK2814514T3 publication Critical patent/DK2814514T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01021—Histidine-tRNA ligase (6.1.1.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)

Claims (25)

1. Terapeutisk præparat, som omfatter et histidyl-tRNA-synthetase-(HRS)-polypeptid med en længde på 500-506 aminosyrer, som er mindst 90% identisk med SEQ ID NO:70 og mangler resterne 507-509 af SEQ ID NO:1, hvor HRS-polypeptidet omfatter mindst én epitop, som specifikt krydsreagerer med et auto-antistof, der er specifikt for histidyl-tRNA-synthetase eller har en antiinflammatorisk aktivitet, og hvor præpara-tet/HRS-polypeptidet er: a) mindst ca. 95% rent; b) mindre end ca. 5% aggregeret; og c) i det væsentlige endotoksinfrit.
2. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet haren længde på 505-506 aminosyrer og er mindst 90% identisk med SEQ ID NO:70.
3. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet omfatter SEQ ID NO:70.
4. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet består af SEQ ID NO:70.
5. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet omfatter SEQ ID NO:166.
6. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet består af SEQ ID NO:166.
7. Terapeutisk præparat ifølge krav 1, hvor HRS-polypeptidet haren mutation af mindst én cysteinrest.
8. Terapeutisk præparat ifølge krav 7, hvor den mindst ene cysteinrest er valgt blandt Cys174, Cys191, Cys224, Cys235 og Cys455.
9. Terapeutisk præparat ifølge et hvilket som helst af kravene 1-8, hvor HRS-polypeptidet har forøget biologisk aktivitet og/eller homogenitet i forhold til et polypeptid ifølge SEQ ID NO:1 under sammenlignelige betingelser, der går fra ca. 4-40°C og en pH på ca. 6,0-8,0.
10. Terapeutisk præparat ifølge krav 9, hvor HRS-polypeptidet har reduceret disulfid-dannelse mellem kæderne under reducerende betingelser i forhold til polypeptidet med SEQ ID NO:1.
11. Terapeutisk præparat ifølge et hvilket som helst af kravene 1-10 til anvendelse til: a) behandling afen muskeldystrofi; b) behandling af en autoimmun eller inflammatorisk sygdom; c) behandling af rhabdomyolyse, muskelsvind, kakeksi, muskelinflammation eller muskelskade; eller d) behandling af en sygdom, som er forbundet med et autoantistof, der er specifikt for histidyl-tRNA-synthetase, hvor HRS-polypeptidet omfatter mindst én epitop, som specifikt krydsreagerer med autoantistoffet, og hvor autoantistoffet er et anti-Jo-1-antistof.
12. Terapeutisk præparat ifølge krav 11(a), hvor muskeldystrofien er valgt blandt Du-chennes muskeldystrofi, Beckers muskeldystrofi, Emery-Dreifuss’ muskeldystrofi, ”Limb girdle’-muskeldystrofi, facioscapulohumeral muskeldystrofi, myotonisk dystrofi, okulofaryngeal muskeldystrofi, distal muskeldystrofi og medfødt muskeldystrofi.
13. Terapeutisk præparat til anvendelse ifølge krav 12, hvor muskeldystrofien er facioscapulohumeral muskeldystrofi.
14. Terapeutisk præparat til anvendelse ifølge krav 13, hvor den facioscapulohumerale muskeldystrofi er indtrådt i spædbarnsalderen eller barndommen.
15. Terapeutisk præparat ifølge krav 11(d), hvor sygdommen er valgt fra gruppen bestående af inflammatoriske myopatier, herunder polymyositis, dermatomyositis og beslægtede lidelser, polymyositis-sklerodermi-overlap, inklusionslegeme-myositis (IBM), anti-synthetasesyndrom, interstitiel lungesygdom, arthritis og Reynauds fænomen.
16. Immunoadsorberende præparat, som omfatter et biokompatibelt fast underlag, som til sig har bundet mindst ét histidyl-tRNA-synthetase-(HRS)-polypeptid som defineret i et hvilket som helst af kravene 1-10, hvor HRS-polypeptidet omfatter mindst én epitop, som specifikt krydsreagerer med et autoantistof, der er specifikt for histidyl-tRNA-synthetase.
17. Immunoadsorberende præparat ifølge krav 16, hvor HRS-polypeptidet er valgt blandt SEQ ID NO:70 og SEQ ID NO:166.
18. Immunoadsorberende præparat ifølge krav 16 eller 17, hvor det biokompatible faste underlag er valgt blandt syntetiske og naturlige polymerer, polysaccharider, polyamider, glaskugler, partikelformigt silika, porøst glas, silika, resiner og syntetiske matrixer, der omfatter acrylamidderivater, methacrylamidderivater og polystyrenderivater.
19. Immunoadsorberende præparat ifølge krav 18, hvor polymeren er valgt blandt agar, alginat, carrageenan, guargummi, gummi arabicum, ghattigummi, tragantgummi, ka-rayagummi, johannesbrødgummi, xanthangummi, agaroser, celluloser, pektiner, muci-ner, dextraner, stivelser, hepariner, chitosaner, hydroxystivelser, hydroxypropylstivel-ser, carboxymethylstivelser, hydroxyethylcelluloser, hydroxypropylcelluloser og car-boxymethylcelluloser.
20. Immunoadsorberende præparat ifølge krav 18, hvor den syntetiske polymer er valgt blandt acrylpolymerer, polyamider, polyimider, polyestere, polyethere, polymere vinylforbindelser, polyalkener og blandinger deraf.
21. Immunoadsorberende præparat ifølge et hvilket som helst af kravene 16-20, hvor HRS-polypeptidet er kovalent bundet til det biokompatible underlag.
22. Fremgangsmåde til ekstra korporal immunoadsorption af anti-histidyl-tRNA-synthe-tase-(HRS)-antistofferfra en ekstracellulær kropsvæske, hvilken fremgangsmåde omfatter, at (a) der tilvejebringes den ekstracellulære kropsvæske, som er blevet opnået fra et individ, (b) den ekstracellulære kropsvæske bringes i kontakt med et biokompatibelt fast underlag, som har mindst ét HRS-polypeptid som defineret i et hvilket som helst af kravene 1-10 bundet dertil, hvorved anti-HRS-antistofferne opfanges på det faste underlag.
23. Fremgangsmåde ifølge krav 22, hvor anti-HRS-antistofferne omfatter et Jo-1-antistof.
24. HRS-polypeptid som defineret i et hvilket som helst af kravene 1-10 til anvendelse i en fremgangsmåde til ekstrakorporal immunoadsorption af anti-histidyl-tRNA-synthe-tase-(HRS)-antistofferfra en ekstracellulær kropsvæske, hvilken fremgangsmåde omfatter, at (a) der tilvejebringes den ekstracellulære kropsvæske, som er blevet opnået fra et individ, (b) den ekstracellulære kropsvæske bringes i kontakt med et biokompatibelt fast underlag, som har HRS-polypeptidet bundet dertil, hvorved anti-HRS-anti-stofferne opfanges på det faste underlag, og (c) den ekstracellulære kropsvæske fra trin (b) reinfunderes i individet.
25. HRS-polypeptid til anvendelse ifølge krav 24 til anvendelse umiddelbart før administration af et HRS-polypeptid.
DK13749967.9T 2012-02-16 2013-02-15 Histidyl-tRNA-synthetaser til behandling af autoimmune og inflammatoriske sygdomme DK2814514T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261599802P 2012-02-16 2012-02-16
US201261655358P 2012-06-04 2012-06-04
US201261725414P 2012-11-12 2012-11-12
PCT/US2013/026494 WO2013123432A2 (en) 2012-02-16 2013-02-15 Histidyl-trna synthetases for treating autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
DK2814514T3 true DK2814514T3 (da) 2017-12-18

Family

ID=48984896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13749967.9T DK2814514T3 (da) 2012-02-16 2013-02-15 Histidyl-tRNA-synthetaser til behandling af autoimmune og inflammatoriske sygdomme

Country Status (14)

Country Link
US (3) US8835387B2 (da)
EP (2) EP2814514B1 (da)
JP (2) JP6170077B2 (da)
KR (1) KR20140123571A (da)
CN (1) CN104334196B (da)
AU (2) AU2013221317B2 (da)
CA (1) CA2864300A1 (da)
DK (1) DK2814514T3 (da)
ES (1) ES2652136T3 (da)
IN (1) IN2014MN01642A (da)
MX (1) MX356107B (da)
NZ (1) NZ628126A (da)
RU (1) RU2659423C2 (da)
WO (1) WO2013123432A2 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8159825B1 (en) 2006-08-25 2012-04-17 Hypres Inc. Method for fabrication of electrical contacts to superconducting circuits
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
EP2408905B1 (en) * 2009-03-16 2017-05-10 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
US12129514B2 (en) 2009-04-30 2024-10-29 Molecular Loop Biosolutions, Llc Methods and compositions for evaluating genetic markers
EP2425240A4 (en) 2009-04-30 2012-12-12 Good Start Genetics Inc METHOD AND COMPOSITION FOR EVALUATING GENETIC MARKERS
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096910A (zh) 2010-04-27 2013-05-08 Atyr医药公司 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2797799C (en) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
AU2011248100B2 (en) 2010-05-04 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CN103124561B (zh) 2010-07-12 2017-05-03 Atyr 医药公司 与天冬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2012048125A2 (en) 2010-10-06 2012-04-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
EP2768983A4 (en) 2011-10-17 2015-06-03 Good Start Genetics Inc METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
AU2012368189B2 (en) 2011-12-29 2017-08-31 Atyr Pharma, Inc. Aspartyl-tRNA synthetase-Fc conjugates
IN2014MN01642A (da) 2012-02-16 2015-07-03 Atyr Pharma Inc
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
US8812422B2 (en) 2012-04-09 2014-08-19 Good Start Genetics, Inc. Variant database
US10227635B2 (en) 2012-04-16 2019-03-12 Molecular Loop Biosolutions, Llc Capture reactions
US20140127688A1 (en) * 2012-11-07 2014-05-08 Good Start Genetics, Inc. Methods and systems for identifying contamination in samples
US8778609B1 (en) 2013-03-14 2014-07-15 Good Start Genetics, Inc. Methods for analyzing nucleic acids
US9587235B2 (en) * 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
EP3005200A2 (en) 2013-06-03 2016-04-13 Good Start Genetics, Inc. Methods and systems for storing sequence read data
US10851414B2 (en) 2013-10-18 2020-12-01 Good Start Genetics, Inc. Methods for determining carrier status
WO2015057565A1 (en) 2013-10-18 2015-04-23 Good Start Genetics, Inc. Methods for assessing a genomic region of a subject
WO2015175530A1 (en) 2014-05-12 2015-11-19 Gore Athurva Methods for detecting aneuploidy
WO2015187502A1 (en) 2014-06-02 2015-12-10 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
WO2016025818A1 (en) 2014-08-15 2016-02-18 Good Start Genetics, Inc. Systems and methods for genetic analysis
US12285472B2 (en) * 2014-08-20 2025-04-29 The Regents Of The University Of California Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
US11408024B2 (en) 2014-09-10 2022-08-09 Molecular Loop Biosciences, Inc. Methods for selectively suppressing non-target sequences
JP2017536087A (ja) 2014-09-24 2017-12-07 グッド スタート ジェネティクス， インコーポレイテッド 遺伝子アッセイのロバストネスを増大させるためのプロセス制御
US10066259B2 (en) 2015-01-06 2018-09-04 Good Start Genetics, Inc. Screening for structural variants
WO2016137280A1 (ko) * 2015-02-26 2016-09-01 재단법인 의약바이오컨버젼스연구단 트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물
CN105001341A (zh) * 2015-07-29 2015-10-28 广州天宝颂原生物科技开发有限公司 一种重组人自身抗原JoSmD1
AU2015416589B2 (en) * 2015-12-10 2021-04-01 Menicon Co., Ltd. Peptide composition
TW201825118A (zh) * 2016-11-30 2018-07-16 美商艾堤爾製藥公司 抗-hrs抗體及用於治療癌症之組合療法
MX2019007110A (es) * 2016-12-14 2019-12-05 Benitec Biopharma Ltd Reactivos para el tratamiento de la distrofia muscular oculofaringea (opmd) y uso de estos.
CN108511044B (zh) * 2017-02-23 2021-12-17 珠海健康云科技有限公司 一种互联网咨询分诊方法及系统
CN110536694A (zh) * 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN108014333B (zh) * 2017-10-11 2020-10-20 江苏省农业科学院 动物用粘膜靶向免疫增强剂及其在兽用疫苗中的应用
JP7490925B2 (ja) * 2018-07-26 2024-05-28 エータイアー ファーマ， インコーポレイテッド Ｎｒｐ２関連疾患を治療するための組成物および方法
CN112755026A (zh) * 2021-03-01 2021-05-07 滨州医学院 雷帕霉素在制备治疗中耳炎药物中的应用
CN112986451B (zh) * 2021-05-06 2022-05-17 湖南师范大学 一种基于风味特征的杂交鱼类肉品质评价方法
IT202100014333A1 (it) * 2021-06-01 2022-12-01 Materias S R L Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2)
EP4482469A4 (en) * 2022-02-24 2026-03-04 Mayo Found Medical Education & Res COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE SYSTEM
CN115960924A (zh) * 2022-11-04 2023-04-14 广州达安基因股份有限公司 重组jo-1抗原的制备方法和应用
CN116790609B (zh) * 2023-08-22 2023-10-27 中国海洋大学 对类胡萝卜素具有高亲和性的核酸适配体及其应用
CN120058951B (zh) * 2025-02-27 2025-11-04 郑州伊美诺生物技术有限公司 抗氨基酰基-tRNA合成酶的单克隆抗体及其应用

Family Cites Families (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4483105A (en) 1983-03-11 1984-11-20 Maschinenfabrik Gehring, Gesellschaft Mit Beschrankter Haftung & Co. Kommanditgesellschaft Device to hold workpieces for the honing of their axial center bore
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5766960A (en) 1987-07-27 1998-06-16 Australian Membrane And Biotechnology Research Institute Receptor membranes
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US4865841A (en) 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
WO1990011294A1 (en) 1989-03-21 1990-10-04 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US6309822B1 (en) 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5480784A (en) 1989-07-11 1996-01-02 Gen-Probe Incorporated Nucleic acid sequence amplification methods
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
DK0552142T3 (da) 1989-07-19 1998-09-07 Connetics Corp T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5556645A (en) 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6075121A (en) 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
WO1992004472A1 (en) 1990-09-07 1992-03-19 Oklahoma Medical Research Foundation Antigens associated with polymyositis and with dermatomyositis
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5936731A (en) 1991-02-22 1999-08-10 Applied Spectral Imaging Ltd. Method for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome painting
US5981606A (en) 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5149691A (en) 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
ES2290976T3 (es) 1992-06-05 2008-02-16 The Scripps Research Institute D-proteina ligada y metodo para identificar compuestos que modulan la actividad de receptores.
US5977079A (en) 1992-08-21 1999-11-02 Alberta Research Council Edmonton Compositions for attenuating antibody- mediated xenograft rejection in human recipients
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5484703A (en) 1993-04-22 1996-01-16 United States Of America Assay using recombinant histidyl-tRNA synthetase
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
DE69431719T2 (de) 1993-06-25 2003-09-18 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Hybridisierung und sequenzierung von nukleinsäuren
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5641867A (en) 1993-09-29 1997-06-24 The Trustees Of Columbia University In The City Of New York Antibody which specifically binds to endothelial-monocyte activating polypeptide II
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
JPH09510351A (ja) 1994-03-16 1997-10-21 ジェン−プローブ・インコーポレイテッド 等温鎖置換核酸増幅法
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
DE69534187T2 (de) 1994-05-13 2005-11-17 Miltenyi Biotec Gmbh Sterile und pyrogenfreie säulen, gekoppelt mit einem protein, zum binden und entfernen von substanzen aus dem blut
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
CA2212992A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Fibroblast growth factor-14
US6013483A (en) 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5843655A (en) 1995-09-18 1998-12-01 Affymetrix, Inc. Methods for testing oligonucleotide arrays
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
WO1997026354A1 (en) 1996-01-19 1997-07-24 Smithkline Beecham Plc HISTIDYL-tRNA SYNTHETASE OF STAPHYLOCOCCUS AUREUS
GB9601067D0 (en) 1996-01-19 1996-03-20 Smithkline Beecham Plc Novel compounds
JPH11503618A (ja) * 1996-01-19 1999-03-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー スタフィロコッカス・アウレウスのロイシル−ｔＲＮＡシンセターゼ
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5837196A (en) 1996-01-26 1998-11-17 The Regents Of The University Of California High density array fabrication and readout method for a fiber optic biosensor
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6114122A (en) 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US6238866B1 (en) 1996-04-16 2001-05-29 The United States Of America As Represented By The Secretary Of The Army Detector for nucleic acid typing and methods of using the same
US5795758A (en) 1997-04-18 1998-08-18 Smithkline Beecham Corporation DNA encoding histidyl tRNA synthetase variant from Streptococcus pneumoniae
GB9607993D0 (en) 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US5853993A (en) 1996-10-21 1998-12-29 Hewlett-Packard Company Signal enhancement method and kit
EP1460083B1 (en) 1996-11-06 2006-01-18 Sequenom, Inc. Analysing method and apparatus
JP3402972B2 (ja) 1996-11-14 2003-05-06 東京エレクトロン株式会社 半導体装置の製造方法
US5804386A (en) 1997-01-15 1998-09-08 Incyte Pharmaceuticals, Inc. Sets of labeled energy transfer fluorescent primers and their use in multi component analysis
US6309824B1 (en) 1997-01-16 2001-10-30 Hyseq, Inc. Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
ATE319856T1 (de) 1997-06-13 2006-03-15 Affymetrix Inc A Delaware Corp Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips
US6333179B1 (en) 1997-06-20 2001-12-25 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids
US5882892A (en) 1997-07-23 1999-03-16 Smithkline Beecham Corporation Asps
US5858720A (en) 1997-07-23 1999-01-12 Smithkline Beecham Corporation Hiss
US6420108B2 (en) 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
WO1999005574A1 (en) 1997-07-25 1999-02-04 Affymetrix, Inc. Method and system for providing a probe array chip design database
EP1019536B1 (en) 1997-08-15 2004-10-20 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6511803B1 (en) 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6054274A (en) 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
US6013449A (en) 1997-11-26 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Probe-based analysis of heterozygous mutations using two-color labelling
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
EP1051523A2 (en) 1998-02-02 2000-11-15 Amersham Pharmacia Biotech AB Nucleic acid analysis method
US6083726A (en) 1998-02-03 2000-07-04 Lucent Technologies, Inc. Methods for polynucleotide synthesis and articles for polynucleotide hybridization
CA2318175A1 (en) 1998-02-04 1999-08-12 Invitrogen Corporation Microarrays and uses therefor
US6428960B1 (en) 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
JP2002505110A (ja) 1998-03-04 2002-02-19 オニックス ファーマシューティカルズ，インコーポレイティド 遺伝物質の高生産性発現のためのバキュロウイルス発現系及び方法
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6284497B1 (en) 1998-04-09 2001-09-04 Trustees Of Boston University Nucleic acid arrays and methods of synthesis
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
US6268210B1 (en) 1998-05-27 2001-07-31 Hyseq, Inc. Sandwich arrays of biological compounds
US6800286B1 (en) 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
US6306643B1 (en) 1998-08-24 2001-10-23 Affymetrix, Inc. Methods of using an array of pooled probes in genetic analysis
US6185561B1 (en) 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6316193B1 (en) 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
EP1124990B1 (en) 1998-10-27 2006-01-18 Affymetrix, Inc. Complexity management and analysis of genomic dna
US6263287B1 (en) 1998-11-12 2001-07-17 Scios Inc. Systems for the analysis of gene expression data
AU776679B2 (en) 1998-11-13 2004-09-16 Children's Hospital Of Los Angeles Methods of facilitating vascular growth
US6309828B1 (en) 1998-11-18 2001-10-30 Agilent Technologies, Inc. Method and apparatus for fabricating replicate arrays of nucleic acid molecules
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6245518B1 (en) 1998-12-11 2001-06-12 Hyseq, Inc. Polynucleotide arrays and methods of making and using the same
US6351712B1 (en) 1998-12-28 2002-02-26 Rosetta Inpharmatics, Inc. Statistical combining of cell expression profiles
US6586802B2 (en) 1999-01-14 2003-07-01 Mitsubishi Denki Kabushiki Kaisha Semiconductor device
US6312906B1 (en) 1999-01-15 2001-11-06 Imperial College Innovations, Ltd. Immobilized nucleic acid hybridization reagent and method
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6177248B1 (en) 1999-02-24 2001-01-23 Affymetrix, Inc. Downstream genes of tumor suppressor WT1
EP1159615A2 (en) 1999-03-10 2001-12-05 National Institutes of Health, as represented by the Secretary, Department of Health and Human Services of the Government Universal protein array system
AU4058100A (en) 1999-04-09 2000-11-14 Arcturus Engineering, Inc. Generic cdna or protein array for customized assays
US6284465B1 (en) 1999-04-15 2001-09-04 Agilent Technologies, Inc. Apparatus, systems and method for locating nucleic acids bound to surfaces
US6268141B1 (en) 1999-05-12 2001-07-31 Beckman Coulter, Inc. Immobilization of unmodified biopolymers to acyl fluoride activated substrates
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
JP2003527087A (ja) 1999-08-13 2003-09-16 イェール・ユニバーシティ バイナリーコード化配列タグ
US6171797B1 (en) 1999-10-20 2001-01-09 Agilent Technologies Inc. Methods of making polymeric arrays
JP2003514828A (ja) 1999-10-27 2003-04-22 セル−サイ・コーポレーシヨン 自己免疫および移植組織に関連する宿主対移植片症状の処置に有用なペプチド構築物の調製法および組成物
US6548060B1 (en) 1999-11-18 2003-04-15 Sunghoon Kim Anti-apoptotic use of human glutaminyl-tRNA synthetase with two consecutive pro-apoptotic mediators
US6372431B1 (en) 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
DE19957827C2 (de) 1999-11-25 2003-06-12 Epigenomics Ag Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche
US6383749B2 (en) 1999-12-02 2002-05-07 Clontech Laboratories, Inc. Methods of labeling nucleic acids for use in array based hybridization assays
US20070042392A1 (en) 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20030158400A1 (en) 2000-02-03 2003-08-21 Tang Y. Tom Novel nucleic acids and polypeptides
US20030165921A1 (en) 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
US20020128187A1 (en) 2000-02-03 2002-09-12 Tang Y. Tom Novel nucleic acids and polypeptides
WO2001057259A1 (en) 2000-02-03 2001-08-09 Research Development Foundation Signaling aptamers that transduce molecular recognition to a differential signal
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US6267152B1 (en) 2000-02-18 2001-07-31 Wisconsin Label Corporation Hang tag and method of applying hang tag to an elongated object
JP3464460B2 (ja) 2000-02-24 2003-11-10 ジー・ケー・エヌ・レブロ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ドライブシャフト
DE10011482B4 (de) 2000-03-09 2004-06-09 Fresenius Hemocare Gmbh Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers
US6376191B1 (en) 2000-03-22 2002-04-23 Mergen, Ltd. Microarray-based analysis of polynucleotide sequence variations
US7273844B2 (en) 2000-03-31 2007-09-25 The Scripps Research Institute Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
US7144984B2 (en) 2000-03-31 2006-12-05 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP2258834B1 (en) 2000-03-31 2015-09-23 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
AU2001289284A1 (en) 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1322818A (zh) 2000-05-09 2001-11-21 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶10和编码这种多肽的多核苷酸
AU2001259631A1 (en) 2000-05-16 2001-11-26 Genway Biotech, Inc. Methods and vectors for generating antibodies in avian species and uses therefor
AU2001256780A1 (en) 2000-05-18 2001-11-26 Nihon University, School Juridical Person Method for examining ischemic conditions
CA2408315A1 (en) 2000-05-25 2001-11-29 Incyte Genomics, Inc. Aminoacyl trna synthetases
JP2003536073A (ja) 2000-06-05 2003-12-02 カイロン コーポレイション プロテオミクス分析を実施するためのマイクロアレイ
AU5114000A (en) 2000-06-14 2001-12-24 Imagene Co., Ltd. P43 anti-tumor therapeutic agent and three dimensional structure of its cytokinedomain
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
US6386749B1 (en) 2000-06-26 2002-05-14 Affymetrix, Inc. Systems and methods for heating and mixing fluids
CN1331293A (zh) * 2000-06-28 2002-01-16 上海博德基因开发有限公司 一种新的多肽——组氨酸tRNA合成酶11.99和编码这种多肽的多核苷酸
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US6380377B1 (en) 2000-07-14 2002-04-30 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
AU2002230381A1 (en) 2000-08-31 2002-04-22 Motorola, Inc. High density column and row addressable electrode arrays
JP2002071687A (ja) 2000-08-31 2002-03-12 Canon Inc 変異遺伝子のスクリーニング方法
CN1341725A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人苏氨酰－tRNA合成酶48.73和编码这种多肽的多核苷酸
CN1341727A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——甲硫氨酰tRNA合成酶35.09和编码这种多肽的多核苷酸
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US7354721B2 (en) 2000-09-22 2008-04-08 Clontech Laboratories, Inc. Highly sensitive proteomic analysis methods, and kits and systems for practicing the same
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1352242A (zh) 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人谷氨酰tRNA合成酶12.65和编码这种多肽的多核苷酸
CN1352252A (zh) 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶11.77和编码这种多肽的多核苷酸
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
JP2004537270A (ja) 2000-12-15 2004-12-16 インサイト・ゲノミックス・インコーポレイテッド アミノアシルｔＲＮＡ合成酵素
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002055663A2 (en) 2001-01-12 2002-07-18 Exelixis, Inc. Srebp pathway modulation through targeting hisrs
US20020183936A1 (en) 2001-01-24 2002-12-05 Affymetrix, Inc. Method, system, and computer software for providing a genomic web portal
US6743619B1 (en) 2001-01-30 2004-06-01 Nuvelo Nucleic acids and polypeptides
WO2002067970A1 (en) 2001-02-23 2002-09-06 The Scripps Research Institute TRYPTOPHANYL-tRNA SYNTHETASE DERIVED POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US6903189B2 (en) 2001-03-21 2005-06-07 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20030215827A1 (en) 2001-05-22 2003-11-20 Henry Yue Aminoacyl trna synthetases
KR100405919B1 (ko) 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
US20040018505A1 (en) 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
US6632611B2 (en) 2001-07-20 2003-10-14 Affymetrix, Inc. Method of target enrichment and amplification
US6872529B2 (en) 2001-07-25 2005-03-29 Affymetrix, Inc. Complexity management of genomic DNA
WO2003009813A2 (en) 2001-07-26 2003-02-06 Novartis Ag Methods of treating neuropilin-mediated diseases
KR100722001B1 (ko) 2001-08-15 2007-05-25 스킨메디카, 인코포레이티드 오르니틴 데카복실라제 억제제의 모낭 전달용 국소 조성물
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040048290A1 (en) 2001-12-13 2004-03-11 Lee Ernestine A Aminoacyl trna synthetases
US7011945B2 (en) 2001-12-21 2006-03-14 Eastman Kodak Company Random array of micro-spheres for the analysis of nucleic acids
US20040101879A1 (en) 2002-01-11 2004-05-27 Cynthia Seidel-Dugan Srebp pathway modulation through targeting hisrs
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
AU2003225910A1 (en) 2002-03-20 2003-10-08 Johns Hopkins University Raav vector compositions and methods for the treatment of choroidal neovascularization
WO2003094848A2 (en) 2002-05-10 2003-11-20 Incyte Corporation Nucleic acid-associated proteins
WO2003094862A2 (en) 2002-05-13 2003-11-20 Rigel Pharmaceuticals, Inc. tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
KR100515016B1 (ko) 2002-07-22 2005-09-15 재단법인서울대학교산학협력재단 ｐ43을 유효성분으로 하는 창상 치료용 약학적 조성물
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US7011949B2 (en) 2002-09-30 2006-03-14 Agilent Technologies, Inc. Methods and compositions for producing labeled probe nucleic acids for use in array based comparative genomic hybridization applications
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004060262A2 (en) 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004064863A1 (en) 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
US7028629B2 (en) 2003-02-03 2006-04-18 Richard Walcome Self-sealing port light assembly
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
WO2005073250A2 (en) 2004-01-28 2005-08-11 Lorantis Limited Medical treatment using an rna1 targeting a human notch signalling pathway member
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
WO2005087953A2 (en) 2004-03-05 2005-09-22 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
KR100599454B1 (ko) 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 ａｉｍ3의 신규 용도
PT1765362E (pt) 2004-06-04 2012-06-04 Scripps Research Inst Composições e métodos para o tratamento de doenças neovasculares
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20060079673A1 (en) 2004-08-02 2006-04-13 Paul Glidden Polynucleotides encoding tRNA synthetase fragments and uses thereof
US20060024288A1 (en) 2004-08-02 2006-02-02 Pfizer Inc. tRNA synthetase fragments
US20060078553A1 (en) 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US8282921B2 (en) 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
EP1657232A1 (en) 2004-11-05 2006-05-17 Cellzome Ag Use of S-enantiomers of alpha-sustituted aryl acetic acids for the prevention of Alzheimer's disease
US8003780B2 (en) 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
KR100903984B1 (ko) 2005-02-01 2009-06-25 주식회사 이매진 Aimp1 폴리펩티드 또는 이의 단편을 유효성분으로 포함하는 피부 노화 방지, 주름 개선, 피부 유연 증진 및 탄력 증진용 화장료 조성물
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2006102170A2 (en) 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
KR100689274B1 (ko) 2005-03-30 2007-03-08 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질
US7842467B1 (en) 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
US7375188B2 (en) 2005-07-29 2008-05-20 Mallinckrodt Baker, Inc. Vegetarian protein a preparation and methods thereof
DE102005043321A1 (de) 2005-09-12 2007-03-22 Fresenius Medical Care Deutschland Gmbh Hohlfasermembrantrennvorrichtung
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
ES2528663T3 (es) 2005-12-02 2015-02-11 The Scripps Research Institute Composiciones de tirosil-ARNt sintetasa angiogénicas y procedimientos
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20090305973A1 (en) 2006-01-23 2009-12-10 Sung-Hoon Kim Novel peptide and use thereof
US8518980B2 (en) * 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
US9181543B2 (en) 2006-05-26 2015-11-10 Obodies Limited OB fold domains
WO2008007818A1 (en) 2006-07-13 2008-01-17 Seoul National University Industry Foundation Novel use of aimp1 for controlling glucose level
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
EP2121739A4 (en) 2007-02-01 2010-03-10 Imagene Co Ltd NOVEL POLYPEPTIDE HAVING ANTITUMOR ACTIVITY
US20100138941A1 (en) 2007-04-27 2010-06-03 Imagene Co., Ltd. Method for screening immune modulator
PL2197900T3 (pl) 2007-08-24 2012-12-31 Univ Wuerzburg J Maximilians Zmutowane podwójnie cyklizowane peptydy receptorowe hamujące przeciwciała przeciwko beta 1-adrenoreceptorowi
KR101067816B1 (ko) 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
US20110104139A1 (en) 2008-03-11 2011-05-05 The University Of North Carolina At Chapel Hill ANGIOSTATIC COMPOSITIONS COMPRISING TRUNCATED TYROSYL-tRNA SYNTHETASE POLYPEPTIDES AND METHODS OF USING SAME
AU2009257538A1 (en) 2008-06-11 2009-12-17 Atyr Pharma, Inc. Thrombopoietic activity of tyrosyl-tRNA synthetase polypeptides
JP5756751B2 (ja) 2008-06-26 2015-07-29 エータイアー ファーマ， インコーポレイテッド 非正準的な生物学的活性を有するグリシル−ｔＲＮＡ合成酵素を含む組成物および方法
AU2008360729A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
KR101067817B1 (ko) 2008-10-10 2011-09-27 서울대학교산학협력단 Ａｉｍｐ1 폴리펩티드에 대한 항체를 포함하는 관절염 진단용 조성물
US8901081B2 (en) 2008-10-10 2014-12-02 Snu R&Db Foundation Uses of GRS proteins or fragments thereof
KR101067815B1 (ko) 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
US20120058133A1 (en) 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
EP2408905B1 (en) 2009-03-16 2017-05-10 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
AU2010236913B2 (en) * 2009-03-31 2016-03-24 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities
KR20210054598A (ko) * 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
WO2011072265A1 (en) * 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating inflammation
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
US8828685B2 (en) 2010-02-04 2014-09-09 The Scripps Research Institute Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
WO2013036296A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers
IN2014MN01642A (da) 2012-02-16 2015-07-03 Atyr Pharma Inc

Also Published As

Publication number Publication date
US8835387B2 (en) 2014-09-16
US20150093799A1 (en) 2015-04-02
EP2814514A2 (en) 2014-12-24
AU2013221317A1 (en) 2014-09-18
EP2814514B1 (en) 2017-09-13
RU2659423C2 (ru) 2018-07-02
AU2017232051A1 (en) 2017-10-12
US20130344096A1 (en) 2013-12-26
WO2013123432A2 (en) 2013-08-22
AU2013221317B2 (en) 2017-07-06
IN2014MN01642A (da) 2015-07-03
CN104334196B (zh) 2018-04-10
CA2864300A1 (en) 2013-08-22
CN104334196A (zh) 2015-02-04
MX2014009706A (es) 2015-01-14
HK1204268A1 (en) 2015-11-13
KR20140123571A (ko) 2014-10-22
JP2015513534A (ja) 2015-05-14
EP2814514A4 (en) 2015-10-07
WO2013123432A3 (en) 2013-10-17
JP2017222665A (ja) 2017-12-21
EP3311847A1 (en) 2018-04-25
ES2652136T3 (es) 2018-01-31
MX356107B (es) 2018-05-15
RU2014137321A (ru) 2016-04-10
JP6330088B2 (ja) 2018-05-23
JP6170077B2 (ja) 2017-07-26
NZ628126A (en) 2016-10-28
US20160369259A1 (en) 2016-12-22
US9273302B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
AU2013221317B2 (en) Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US20140066321A1 (en) Structures of human histidyl-trna synthetase and methods of use
CA2798301C (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases
JP6397479B2 (ja) ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
AU2011261486B2 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
KR102099730B1 (ko) 아스파르틸­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
CA2800375C (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
KR20130102534A (ko) 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
HK1204268B (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
HK40006273A (en) Histidyl-trna synthetase-fc conjugates
HK40006273B (en) Histidyl-trna synthetase-fc conjugates
HK1220226B (en) Histidyl-trna synthetase-fc conjugates